Brain scan study tests new depression Drug's target binding
NCT ID NCT07329621
First seen Jan 10, 2026 · Last updated May 17, 2026 · Updated 21 times
Summary
This early-stage study tests how well the experimental drug MSP-2020 attaches to serotonin receptors in the brains of 18 healthy men. Researchers will measure drug levels in the blood and check for side effects. The goal is to understand how the drug works in the body before testing it in people with depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INCOMPLETE RESPONSE - MAJOR DEPRESSIVE DISORDER (IR-MDD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HMR Hammersmith Medicines Research Ltd.
RECRUITINGLondon, United Kingdom
Conditions
Explore the condition pages connected to this study.